{"id":"cpt-11-based-regimens","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to DNA damage and apoptosis in rapidly dividing cancer cells. CPT-11 is a prodrug that is converted to its active metabolite SN-38, which is responsible for its therapeutic effects.","oneSentence":"CPT-11 is a topoisomerase I inhibitor that works by stabilizing the cleavage complex of DNA and RNA, thereby inhibiting DNA replication and transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:29:31.449Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma","enrollment":236},{"nctId":"NCT03794349","phase":"PHASE2","title":"Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-07-08","conditions":"High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma","enrollment":94},{"nctId":"NCT04920032","phase":"PHASE1","title":"Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2021-08-26","conditions":"Colon Adenocarcinoma, Colorectal Cancer","enrollment":22},{"nctId":"NCT01897454","phase":"PHASE2","title":"Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2012-01-27","conditions":"Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer","enrollment":23},{"nctId":"NCT00098787","phase":"PHASE2","title":"Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-09-08","conditions":"Colorectal Cancer","enrollment":247},{"nctId":"NCT05160896","phase":"PHASE2","title":"SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-11-12","conditions":"Advanced Metastatic Colorectal Cancer","enrollment":90},{"nctId":"NCT03380689","phase":"PHASE1","title":"Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Fujian Cancer Hospital","startDate":"2018-01-05","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT01498289","phase":"PHASE2","title":"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2012-02","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer","enrollment":213},{"nctId":"NCT01039506","phase":"","title":"An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2009-10-15","conditions":"Metastatic Colorectal Cancer","enrollment":1376},{"nctId":"NCT02508077","phase":"PHASE2","title":"FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2016-02-16","conditions":"Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer","enrollment":1},{"nctId":"NCT00861783","phase":"PHASE1","title":"Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2008-06","conditions":"Hepatoma, Advanced Solid Tumor","enrollment":16},{"nctId":"NCT01523431","phase":"PHASE2, PHASE3","title":"Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"The Affiliated Hospital of the Chinese Academy of Military Medical Sciences","startDate":"2012-03-08","conditions":"Metastatic Colorectal Cancer","enrollment":583},{"nctId":"NCT01424709","phase":"PHASE2","title":"Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Tongji University","startDate":"2010-12","conditions":"Non-small Cell Lung Cancer","enrollment":120},{"nctId":"NCT00499369","phase":"PHASE3","title":"Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-06","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer","enrollment":72},{"nctId":"NCT01282658","phase":"","title":"Pharmacogenomics Study of CPT-11 as the First-line Chemotherapy for mCRC","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2010-11","conditions":"Colorectal Cancer","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":323,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FOLFIRI, CPT-11+S-1, CPT-11"],"phase":"phase_2","status":"active","brandName":"CPT-11 based regimens","genericName":"CPT-11 based regimens","companyName":"Daiichi Sankyo Co., Ltd.","companyId":"daiichi-sankyo-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CPT-11 is a topoisomerase I inhibitor that works by stabilizing the cleavage complex of DNA and RNA, thereby inhibiting DNA replication and transcription. Used for Metastatic colorectal cancer, Metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}